Top of this page
Skip navigation, go straight to the content

CNS press releases

New data for Vimpat® (lacosamide) showed sustained efficacy for up to 5 years and improved seizure control when added to a broad range of antiepileptic drugs29-June-2010 | pdf file, 134 kb
Neupro® (rotigotine) significantly improved wellbeing and daily activities impaired due to limb pain associated with Restless Legs Syndrome18-June-2010 | pdf file, 117 kb
Neupro® (rotigotine) showed significant benefit on early morning motor control, sleep and nocturnal symptoms in patients with Parkinson’s disease17-June-2010 | pdf file, 101 kb
New study showed the impact of gastrointestinal disorders in patients with Parkinson’s disease15-June-2010 | pdf file, 55 kb
Excellence in Epilepsy Journalism Award
International Bureau for Epilepsy and UCB launch the 2010 journalism award to recognise outstanding reporting on epilepsy27-April-2010 | pdf file, 69 kb
Data presented at the American Academy of Neurology Meeting demonstrated long-term efficacy and tolerability of Vimpat® (lacosamide)15-April-2010 | pdf file, 92 kb
New data presented at the American Academy of Neurology meeting showed that Neupro® (rotigotine transdermal system) improved both motor and non-motor symptoms of Parkinson's disease14-April-2010 | pdf file, 79 kb
New data showed sustained 5-year benefit of Neupro® (rotigotine) on symptoms of Restless Legs Syndrome13-April-2010 | pdf file, 86 kb
Evidence suggests that sleep is a common problem for people with a wide range of neurological conditions19-March-2010 | pdf file, 60 kb
Excellence in Epilepsy Journalism Award
IBE and UCB announce winners of award to improve understanding of epilepsy around the world20-October-2009 | pdf file, 43 kb
New analysis of pooled clinical data showed VIMPAT® (lacosamide) significantly improved partial-onset seizure control, increased seizure freedom rates and enhanced patient function29-June-2009 | pdf file, 197 kb
Jazz Pharmaceuticals and UCB announce second Phase III study of sodium oxybate in patients with fibromyalgia meets primary endpoints24-June-2009 |pdf file, 67 kb
UCB and PatientsLikeMe partner to give people with epilepsy a voice in advancing research15-Jun-2009 | pdf file, 59 kb
Clinical data presented at International Congress showed treatment with Neupro® (rotigotine) significantly improved early morning akinesia and was generally well tolerated over four years12-Jun-2009 |pdf file, 81 kb
Clinical data presented at International Congress showed treatment with Neupro® (rotigotine) offers high rates of clinical remission and symptom freedom to patients with moderate to severe restless legs syndrome12-Jun-2009 |pdf file, 82 kb
Final call for entries to the ‘Excellence in Epilepsy’ Journalism Award08-June-2009 |pdf file, 40 kb
UCB receives CHMP positive opinion on bringing Neupro® back to all patients in Europe29-May-2009 | pdf file, 94 kb
UCB launches Vimpat® in the U.S. for add-on treatment of epilepsy in adults26-May-2009 | pdf file, 106 kb
UCB announces first results from Phase III brivaracetam studies in epilepsy28-Apr-2009 | pdf file, 53 kb
UCB announces top-line outcomes for proof-of-concept studies20-Feb-2009 | pdf file, 45 kb
UCB to divest Equasym®20-Feb-2009 | pdf file, 51 kb